- Home
- PCVX vs CHE Comparison
PCVX vs CHE Comparison
Compare PCVX & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | CHE |
|---|---|---|
| Founded | 2013 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.2B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCVX | CHE |
|---|---|---|
| Price | $46.23 | $434.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $101.67 | ★ $574.25 |
| AVG Volume (30 Days) | ★ 1.5M | 142.3K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 0.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 18.95 |
| Revenue | N/A | ★ $2,530,634,000.00 |
| Revenue This Year | N/A | $5.91 |
| Revenue Next Year | N/A | $6.21 |
| P/E Ratio | ★ N/A | $22.81 |
| Revenue Growth | N/A | ★ 6.45 |
| 52 Week Low | $27.66 | $408.42 |
| 52 Week High | $93.77 | $623.61 |
Technical Indicators
Market Signals| Indicator | PCVX | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 51.13 |
| Support Level | $42.40 | $425.50 |
| Resistance Level | $48.65 | $436.21 |
| Average True Range (ATR) | 1.54 | 7.39 |
| MACD | 0.16 | 1.03 |
| Stochastic Oscillator | 64.49 | 71.80 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About CHE Chemed Corp
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.